Berglund U, von Schenck H, Wallentin L
Thromb Haemost. 1985 Dec 17;54(4):808-12.
The effects of ticlopidine (T) (500 mg daily) on platelet function were investigated in a double-blind placebo-controlled study in 38 middle-aged men with stable incapacitating angina pectoris. The in vitro platelet reactivity to aggregating agents, the platelet sensitivity to prostacyclin and the plasma levels of platelet specific proteins and fibrinogen were determined before and after 4 and 8 weeks of treatment. T exerted a potent inhibitory effect on ADP-and collagen-induced platelet aggregation. The effect of T was proportional to the pretreatment reactivity to ADP and collagen. The inhibitory effect of T on the epinephrine response was less pronounced. The plasma levels of beta-thromboglobulin, platelet factor 4 and fibrinogen were not influenced by T. The platelet inhibition of prostacyclin was potentiated by T, and it was demonstrated that T and prostacyclin had synergistic inhibitory effects on platelet aggregation.
在一项双盲、安慰剂对照研究中,对38名患有稳定型失能性心绞痛的中年男性,研究了噻氯匹定(T)(每日500毫克)对血小板功能的影响。在治疗4周和8周前后,测定了体外血小板对聚集剂的反应性、血小板对前列环素的敏感性以及血小板特异性蛋白和纤维蛋白原的血浆水平。T对ADP和胶原诱导的血小板聚集具有强大的抑制作用。T的作用与预处理时对ADP和胶原的反应性成正比。T对肾上腺素反应的抑制作用不太明显。T对β-血小板球蛋白、血小板因子4和纤维蛋白原的血浆水平没有影响。T增强了血小板对前列环素的抑制作用,并且证明T和前列环素对血小板聚集具有协同抑制作用。